Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT

Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT / Ye, Y.; Labopin, M.; Chen, J.; Wu, D.; Gedde-Dahl, T.; Blaise, D.; Socie, G.; Forcade, E.; Salmenniemi, U.; Maury, S.; Versluis, J.; Bazarbachi, A.; Nagler, A.; Brissot, E.; Li, L.; Luo, Y.; Shi, J.; Ciceri, F.; Huang, H.; Mohty, M.; Gorin, N. C.. - In: BLOOD CANCER JOURNAL. - ISSN 2044-5385. - 14:1(2024). [10.1038/s41408-024-01072-0]